Member Posts > Cardiol Therapeutics' CRD-38 and Its Role in Restoring Energy Balance in the Failing Heart
Cardiol Therapeutics' CRD-38 is an innovative cannabidiol-based therapy designed to combat mitochondrial dysfunction, a key driver of heart failure (HF). The heart is a highly energy-dependent organ, and mitochondrial impairment leads to decreased ATP production, increased oxidative stress, and cardiomyocyte death, all of which contribute to HF progression. CRD-38 aims to restore mitochondrial function by reducing inflammation and oxidative stress, while also activating PPAR-γ, a regulator of mitochondrial biogenesis. In preclinical models, CRD-38 has been shown to enhance mitochondrial respiration, reduce oxidative damage, and improve overall cardiac function. This targeted approach is particularly beneficial for patients with HFpEF, who experience metabolic inefficiencies that worsen disease outcomes. With promising preclinical results, Cardiol Therapeutics is advancing CRD-38 through regulatory pathways, bringing new hope for patients with limited treatment options. Clinical trials will determine whether CRD-38 can fulfill its potential as a novel heart failure therapy.

#CardiolTherapeutics #HeartFailureTreatment #BiotechInvesting #ClinicalTrials #CBDTherapeutics #HeartHealth #MedicalInnovation #PharmaceuticalBreakthroughs #CRD38